Table 3.
Enrichment Analysis of Breast Cancer Related Markers
| PathwayID | PathwayName | N | P-value | AE | RE | MJI |
|---|---|---|---|---|---|---|
| hsa05212 | Pancreatic cancer | 72 | 3.74E-08 | 7 | 75.59 | 0.2819 |
| hsa05213 | Endometrial cancer | 53 | 1.07E-07 | 6 | 88.02 | 0.2566 |
| hsa05215 | Prostate cancer | 100 | 1.07E-07 | 7 | 54.43 | 0.2683 |
| hsa05223 | Non-small cell lung cancer | 60 | 1.60E-07 | 6 | 77.75 | 0.25 |
| hsa05218 | Melanoma | 72 | 3.55E-07 | 6 | 64.79 | 0.2417 |
| hsa05200 | Pathways in cancer | 348 | 1.02E-06 | 9 | 20.11 | 0.3129 |
| hsa05219 | Bladder cancer | 42 | 1.02E-06 | 5 | 92.56 | 0.2262 |
| h_RacCycDPathway | Influence of Ras and Rho proteins on G1 to S Transition | 26 | 6.66E-06 | 4 | 119.62 | 0.2103 |
| hsa05214 | Glioma | 69 | 6.66E-06 | 5 | 56.34 | 0.2029 |
| hsa05220 | Chronic myeloid leukemia | 74 | 7.91E-06 | 5 | 52.54 | 0.2005 |
| hsa05166 | HTLV-I infection | 272 | 1.71E-05 | 7 | 20.01 | 0.2462 |
| hsa05222 | Small cell lung cancer | 90 | 1.71E-05 | 5 | 43.2 | 0.1944 |
| 200124 | E-cadherin signaling in the nascent adherens junction | 39 | 2.10E-05 | 4 | 79.75 | 0.1846 |
| 200141 | FOXM1 transcription factor network | 41 | 2.37E-05 | 4 | 75.86 | 0.1821 |
| 200190 | a6b1 and a6b4 Integrin signaling | 46 | 3.40E-05 | 4 | 67.61 | 0.1768 |
| hsa04110 | Cell cycle | 124 | 5.80E-05 | 5 | 31.35 | 0.1868 |
| hsa05210 | Colorectal cancer | 62 | 8.23E-05 | 4 | 50.16 | 0.1656 |
| 200041 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | 80 | 1.67E-05 | 4 | 38.88 | 0.1583 |
| DiseaseID | DiseaseName | N | P-value | AE | RE | MJI |
| MESH:D002528 | Cerebellar Neoplasms | 332 | 6.34E-07 | 9 | 32.39 | 0.3136 |
| MESH:D020967 | Myotonic Disorders | 278 | 1.87E-05 | 7 | 30.09 | 0.2459 |
| MESH:D042883 | Choledocholithiasis | 157 | 1.87E-05 | 6 | 45.67 | 0.2191 |
| MESH:D002282 | Adenocarcinoma, Bronchiolo-Alveolar | 339 | 3.44E-05 | 7 | 24.68 | 0.2437 |
| MESH:D009134 | Muscular Atrophy, Spinal | 1119 | 3.44E-05 | 11 | 11.75 | 0.3716 |
| MESH:D016510 | Corneal Neovascularization | 669 | 3.44E-05 | 9 | 16.08 | 0.3067 |
| MESH:D044483 | Intestinal Polyposis | 120 | 4.42E-05 | 5 | 49.79 | 0.1875 |
| PA443756 | Colonic Neoplasms | 122 | 4.42E-05 | 5 | 48.98 | 0.1872 |
| PA445062 | Neoplasms | 237 | 4.42E-05 | 6 | 30.25 | 0.2127 |
| MESH:D007972 | Leukoplakia, Oral | 238 | 4.42E-05 | 6 | 30.13 | 0.2126 |
| MESH:D003123 | Colorectal Neoplasms, Hereditary Nonpolyposis | 126 | 4.42E-05 | 5 | 47.42 | 0.1865 |
| MESH:D046152 | Gastrointestinal Stromal Tumors | 148 | 8.01E-05 | 5 | 40.37 | 0.1836 |
| DrugID | DrugName | N | P-value | AE | RE | MJI |
| PA451581 | tamoxifen | 74 | 1.83E-03 | 5 | 18.03 | 0.2124 |
| PA131301952 | gefitinib | 39 | 1.83E-03 | 4 | 27.36 | 0.1941 |
| PA152241907 | lapatinib | 14 | 1.83E-03 | 3 | 57.17 | 0.2143 |
| PA449383 | docetaxel | 77 | 9.81E-03 | 4 | 13.86 | 0.1688 |
| PA449509 | estrogens | 79 | 9.89E-03 | 4 | 13.51 | 0.1682 |
| OrganID | OrganName | N | P-value | AE | RE | MJI |
| larynx | larynx | 88 | 1.97E-2 | 2 | 25.45 | 0.2114 |